Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pivotal Therapeutics Inc PVTTF

Healthcare Drug Manufacturers - Specialty & Generic
Pivotal Therapeutics Inc is a Canada based pharmaceutical company. It focuses on Omega-3 therapies for cardiovascular disease and overall health. The products of the company are VASCAZEN which is a prescription-only medical food for the treatment of an Omega-3 Deficiency in patients with cardiovascular disease, OMAZEN, and BENEFISHIAL which provides pure Omega-3 fatty acids for the maintenance of health. The firm operates in the United States and Canada of which majority of the revenue is derived from the United States.


GREY:PVTTF - Post by User

Pivotal Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by 1nvest0rson Oct 04, 2013 3:05pm
381 Views
Post# 21792169

News on Pivotal Therapeutics

News on Pivotal Therapeutics

Pivotal Therapeutics to raise $5 mln through debt financing, $2.7 mln equity raise completed

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities